SPDR S&P Biotech ETF (XBI) Position Reduced by Exencial Wealth Advisors LLC

Exencial Wealth Advisors LLC lowered its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 5.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,014 shares of the exchange traded fund’s stock after selling 848 shares during the period. Exencial Wealth Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $1,005,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in XBI. Northern Trust Corp lifted its position in SPDR S&P Biotech ETF by 56.9% in the second quarter. Northern Trust Corp now owns 4,935 shares of the exchange traded fund’s stock valued at $470,000 after purchasing an additional 1,789 shares during the period. Bank of Montreal Can lifted its position in SPDR S&P Biotech ETF by 19.5% in the third quarter. Bank of Montreal Can now owns 229,588 shares of the exchange traded fund’s stock valued at $22,011,000 after purchasing an additional 37,396 shares during the period. Global Retirement Partners LLC lifted its position in SPDR S&P Biotech ETF by 24.2% in the third quarter. Global Retirement Partners LLC now owns 11,076 shares of the exchange traded fund’s stock valued at $1,062,000 after purchasing an additional 2,159 shares during the period. Howard Capital Management lifted its position in SPDR S&P Biotech ETF by 2.5% in the third quarter. Howard Capital Management now owns 154,827 shares of the exchange traded fund’s stock valued at $14,843,000 after purchasing an additional 3,780 shares during the period. Finally, Patten & Patten Inc. TN lifted its position in SPDR S&P Biotech ETF by 15.6% in the third quarter. Patten & Patten Inc. TN now owns 9,880 shares of the exchange traded fund’s stock valued at $947,000 after purchasing an additional 1,335 shares during the period.

Shares of NYSEARCA:XBI opened at $84.42 on Wednesday. SPDR S&P Biotech ETF has a 52 week low of $64.38 and a 52 week high of $101.55.

WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2019/02/13/spdr-sp-biotech-etf-xbi-position-reduced-by-exencial-wealth-advisors-llc.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit